We Expect WuXi Biologics' Growth to Lag Peers

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations with its "follow and win the molecule" and global dual sourcing strategies. It provides end-to-end services for biologic drugs, from drug discovery to clinical and commercial manufacturing. Unlike its global peers, WuXi specializes in biologic therapeutic modalities. It has one of the largest bioreactor capacities with manufacturing sites worldwide. Riding on the structural shift from small molecule drugs to biologic drugs, WuXi has been growing at a compound annual rate of 47.7% for the past nine years, much faster than global pharmaceutical sales or global CDMOs.